TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06667076: A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination With Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination With Platinum-Based Chemotherapy as Second-line Trea

Sponsor: Janssen Research & Development, LLC · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 480 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$554,400

Rescue Site Savings

+$369,600

Unlock Full NCT06667076 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06667076 Rescue Dossier →